RXi Acquisition of Apthera Builds Breast Cancer Assets

April 2011
Bioworld Week;4/4/2011, Vol. 19 Issue 14, p5
The article reports on the merger between RXi Pharmaceuticals Corp. and Apthera Inc. towards the clinical development of cancer vaccines in the U.S.


Related Articles

  • Product Review.  // Urology Times;Jun2004, Vol. 32 Issue 9, p22 

    Reports on developments in cancer treatment in the U.S. as of June 15, 2004. Agreement between MedImmune Inc. and Cerus Corp. to develop and commercialize a novel therapeutic vaccine to treat several kinds of cancer; Grant of fast track status to BAY 43-9006, treatment for metastatic renal cell...

  • Troubled Cell Genesys Signs Merger Deal with BioSante.  // BioWorld Today;7/1/2009, Vol. 20 Issue 125, p2 

    The article reports on a $38 million all-stock merger deal signed by the board of Cell Genesys Inc. with BioSante Pharmaceuticals Inc. The decision of the board was influenced by the failure of the Phase II trials for its cancer vaccine GVAX in 2008. Under the terms of the deal, BioSante will...

  • Dr. Roger Perlmutter. Flynn, Mary Kathleen // Mergers & Acquisitions: The Dealermaker's Journal;Mar2012, Vol. 47 Issue 3, p24 

    The article reports on dealmaker of the year Dr. Roger Perlmutter who is Amgen's executive vice president, research and development. It informs on how Amgen made year's smartest middle-market M&A play in pharmaceutical industry after it bought BioVex Croup Inc. including how it hedged its bets...

  • News in brief.  // Nature Reviews Drug Discovery;Jul2006, Vol. 5 Issue 7, p530 

    The article presents news briefs related to the recent developments in the pharmaceutical industry. Merck & Co. Inc.'s cervical cancer vaccine Gardasil has successfully passed the regulatory and scientific hurdles, but other hurdles might prove to be more problematic. Studies have shown that the...

  • MERCK: Announces productive 2006; releases new products this year. May, Jonathan // Caribbean Business;11/30/2006, Vol. 34 Issue 47, pS14 

    The article focuses on business developments at Merck & Co. Inc. in Puerto Rico. The firm posted almost $1 billion net income for the period, reflecting the recognition of the medical value of Gardasil, a vaccine for cervical cancer launched in June 2006. Also, Merck has acquired Sirna...

  • Gauging Investment in High-Potency Manufacturing. Van Arnum, Patricia // Pharmaceutical Technology;Jul2013, Vol. 37 Issue 7, p50 

    The article discusses investment in high-potency manufacturing of oncology drugs to expand capabilities in active pharmaceutical ingredients (APIs) in context of antibody drug conjugates (ADCs). It mentions about first U.S. Food and Drug Administration (FDA)-approved ADC Kadcyla, for treating...

  • Infectious Diseases News Round-Up.  // PharmaWatch: Monthly Review;Dec2009, Vol. 8 Issue 12, p19 

    The article offers news briefs on treatment for infectious diseases. GlaxoSmithKline has won U.S. Food and Drug Administration(FDA) approval for cervical cancer vaccine Cervarix. Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group SA, announced positive final analyses of data from...

  • NEWS HEADLINES: Biotechnology.  // PharmaWatch: Biotechnology;June 2003, Vol. 2 Issue 6, p16 

    Reports developments in the biotechnology industry as of June 2003. Resumption of patient enrollment in the two international phase III clinical trials of the Canvaxin therapeutic cancer vaccine from CancerVax Corp.; Details of the merger agreement signed by GenVec Inc. and Diacrin Inc.;...

  • GE Acquires Infographic Systems.  // SDM: Security Distributing & Marketing;Dec2002, Vol. 32 Issue 12, p19 

    Reports on the acquisition of Infographic Systems by General Electric Industrial Systems in Connecticut. Provision of electronic access control; Availability of video imaging; Improvement of electronic security.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics